A later study in a large cohort of Chinese CML-AP and CML-BP patients identified missense, nonsense, and frameshift RUNX1 mutations displaying a reduced transactivation activity and/or a dominant-negative function over the wild-type RUNX1 in 12% of the cases [73]. This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.